The approval is supported by data from the phase 3 PIVOT-PO trial, in which tebipenem demonstrated noninferiority to imipenem-cilastatin. This decision marks the first approval of an oral carbapenem ...
OV-DQUO is an open-vocabulary detection framework that learns from open-world unknown objects through wildcard matching and contrastive denoising training methods, mitigating performance degradation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results